Pancreatic Cancer Research

ResearcherOregon Health & Science UniversityActive in the last 2 years

Charles D. Lopez

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0921-4932; OpenAlex author ID A5102820361. Sources: ClinicalTrials.gov.

Their work

Papers
25 (first author 1, last author 0)
Trials
7 (principal investigator on 7)
Grants
0
Labs led
0
Collaborators
116
Papers, trials and grants by year

2008: 1 trial · 2009: none · 2010: none · 2011: 1 paper · 2012: none · 2013: none · 2014: 1 paper · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: 1 paper, 1 trial · 2020: 1 paper · 2021: 2 papers, 1 trial · 2022: 1 paper, 1 trial · 2023: 6 papers · 2024: 3 papers, 1 trial · 2025: 3 papers, 1 trial · 2026: 5 papers, 1 trial

Papers 25

  1. Schedule-dependent efficacy of gemcitabine and RAS(ON) inhibition in orthotopic pancreatic cancer: implications for clinical trial design. Co-author DOI 10.1016/j.canlet.2026.218864↗
  2. Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial. Co-author DOI 10.1038/s41591-026-04327-4↗
  3. Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I/IIb MORPHEUS-PDAC umbrella study. Co-author DOI 10.1093/oncolo/oyag023↗
  4. IFNγ-dependent tumor-cell MHC-II is restrained by MAPK signaling and associated with immunotherapy responsiveness in pancreatic ductal adenocarcinoma. Co-author DOI 10.1158/2326-6066.cir-25-1612↗
  5. Increased Glucose Availability Sensitizes Pancreatic Cancer to Macrophage-Targeting Immunotherapies. Co-author DOI 10.1158/2767-9764.crc-25-0338↗
  6. Ongoing replication stress tolerance and clonal T cell responses distinguish liver and lung recurrence and outcomes in pancreatic cancer. Co-author DOI 10.1038/s43018-024-00881-3↗
  7. Early detection of pancreatic cancer by a high-throughput protease-activated nanosensor assay. Co-author DOI 10.1126/scitranslmed.adq3110↗
  8. A window trial in metastatic pancreatic ductal adenocarcinoma reveals resistance mechanisms to targeting the KRAS-MEK pathway Co-author DOI 10.64898/2025.12.12.693851↗
  9. CASPER: A Phase I trial combining calaspargase pegol-mnkl and cobimetinib in pancreatic cancer. Co-author DOI 10.1080/14796694.2024.2395235↗
  10. A high throughput blood-based assay for the early detection of pancreatic cancer Co-author DOI 10.1101/2024.01.12.24301220↗
  11. Circulating Neoplastic-Immune Hybrid Cells Are Biomarkers of Occult Metastasis and Treatment Response in Pancreatic Cancer. Co-author DOI 10.3390/cancers16213650↗
  12. Socioeconomic and Geographic Disparities in the Referral and Treatment of Pancreatic Cancer at High-Volume Centers. Co-author DOI 10.1001/jamasurg.2022.6709↗
  13. Phase 2 study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node-positive pancreatic… Co-author DOI 10.1002/cam4.5971↗
  14. Neoadjuvant therapy does not impact the biliary microbiome in patients with pancreatic cancer. Co-author DOI 10.1002/jso.27281↗
  15. Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study P… Co-author DOI 10.1093/oncolo/oyad022↗
  16. Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jitc-2022-005425↗
  17. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  18. Neoadjuvant Therapy Is Associated with Improved Chemotherapy Delivery and Overall Survival Compared to Upfront Resection in Pancreatic Cancer without Increasin… Co-author DOI 10.3390/cancers14030609↗
  19. Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gem… Co-author DOI 10.1200/jco.20.02232↗
  20. Tumor-Infiltrating Leukocyte Phenotypes Distinguish Outcomes in Related Patients With Pancreatic Adenocarcinoma. Co-author DOI 10.1200/po.20.00287↗
  21. Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer. Co-author DOI 10.1136/jitc-2020-000587↗
  22. Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-18-0717↗
  23. Chemoradiation for Locally Advanced Unresectable Pancreatic Cancer-What Now? First author DOI 10.1001/jamaoncol.2016.3012↗
  24. Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer. Co-author DOI 10.1158/1541-7786.mcr-13-0542↗
  25. Lapatinib and gemcitabine for metastatic pancreatic cancer. A phase II study. Co-author DOI 10.1097/coc.0b013e3181d26b01↗

Trials 7

  1. OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma Principal investigator NCT07089940↗
  2. A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer Principal investigator NCT06630325↗
  3. Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Duct… Principal investigator NCT06398587↗
  4. Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer Principal investigator NCT05034627↗
  5. NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Adv… Principal investigator NCT04539808↗
  6. Targeted Pathway Inhibition in Patients With Pancreatic Cancer Principal investigator NCT04005690↗
  7. A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreati… Principal investigator NCT01181245↗

Closest collaborators

The 25 strongest of 116 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Rosalie C. Sears · 11 shared papers, 2014–2026 · strength 1.82
  2. Brett C. Sheppard · 11 shared papers, 2014–2025 · strength 1.62
  3. Adel Kardosh · 7 shared papers, 2022–2026 · strength 1.16
  4. Lisa M. Coussens · 6 shared papers, 2021–2026 · strength 1.01
  5. Jonathan Robert Brody · 5 shared papers, 2024–2026 · strength 0.96
  6. Aaron J. Grossberg · 5 shared papers, 2022–2026 · strength 0.88
  7. Gordon Brent Mills · 5 shared papers, 2024–2026 · strength 0.86
  8. Skye C. Mayo · 5 shared papers, 2022–2024 · strength 0.79
  9. Ranish K. Patel · 4 shared papers, 2023–2025 · strength 0.74
  10. Katie E. Blise · 3 shared papers, 2025–2026 · strength 0.61
  11. Melissa H. Wong · 3 shared papers, 2024–2025 · strength 0.57
  12. Teresa Mercade Macarulla · 3 shared papers, 2021–2026 · strength 0.49
  13. Kyle P. Gribbin · 2 shared papers, 2026 · strength 0.49
  14. Katelyn T. Byrne · 2 shared papers, 2026 · strength 0.49
  15. Thomas Lee Sutton · 3 shared papers, 2022–2023 · strength 0.47
  16. Jason M. Link · 3 shared papers, 2021–2025 · strength 0.43
  17. Gina M. Vaccaro · 3 shared papers, 2017–2023 · strength 0.42
  18. Emerson Yu-sheng Chen · 3 shared papers, 2022–2024 · strength 0.41
  19. Jose L. Montoya Mira · 2 shared papers, 2024–2025 · strength 0.40
  20. Jared Michael Fischer · 2 shared papers, 2024–2025 · strength 0.40
  21. Eileen Mary O'Reilly · 2 shared papers, 2023–2026 · strength 0.38
  22. Do‐Youn Oh · 2 shared papers, 2023–2026 · strength 0.38
  23. Jens Thomas Siveke · 2 shared papers, 2023–2026 · strength 0.38
  24. Jill Lacy · 2 shared papers, 2023–2026 · strength 0.38
  25. Gulam Abbas Manji · 2 shared papers, 2023–2026 · strength 0.38

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.